Robert M Krug

List of Publications by Year
in descending order

30 papers	3,743 citations	257450 24 h-index	454955 30 g-index
50 all docs	50 docs citations	50 times ranked	3661 citing authors

#	Article	IF	Citations
1	Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture. Cell Reports, 2021, 35, 109133.	6.4	53
2	A double-stranded RNA platform is required for the interaction between a host restriction factor and the NS1 protein of influenza A virus. Nucleic Acids Research, 2020, 48, 304-315.	14.5	14
3	Modeling mitigation of influenza epidemics by baloxavir. Nature Communications, 2020, 11, 2750.	12.8	36
4	Avian Influenza Virus PB1 Gene in H3N2 Viruses Evolved in Humans To Reduce Interferon Inhibition by Skewing Codon Usage toward Interferon-Altered tRNA Pools. MBio, 2018, 9, .	4.1	33
5	Nuclear TRIM25 Specifically Targets Influenza Virus Ribonucleoproteins to Block the Onset of RNA Chain Elongation. Cell Host and Microbe, 2017, 22, 627-638.e7.	11.0	94
6	Influenza B virus non-structural protein 1 counteracts ISG15 antiviral activity by sequestering ISGylated viral proteins. Nature Communications, 2016, 7, 12754.	12.8	79
7	A Second RNA-Binding Site in the NS1 Protein of Influenza B Virus. Structure, 2016, 24, 1562-1572.	3.3	12
8	Role of N Terminus-Truncated NS1 Proteins of Influenza A Virus in Inhibiting IRF3 Activation. Journal of Virology, 2016, 90, 4696-4705.	3.4	36
9	Functions of the influenza A virus NS1 protein in antiviral defense. Current Opinion in Virology, 2015, 12, 1-6.	5.4	160
10	Battle between influenza A virus and a newly identified antiviral activity of the PARP-containing ZAPL protein. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14048-14053.	7.1	90
11	An RNA-synthesizing machine. Nature, 2014, 516, 338-339.	27.8	6
12	Exploring naphthyl-carbohydrazides as inhibitors of influenza A viruses. European Journal of Medicinal Chemistry, 2014, 71, 81-90.	5.5	20
13	19F NMR Reveals Multiple Conformations at the Dimer Interface of the Nonstructural Protein 1 Effector Domain from Influenza A Virus. Structure, 2014, 22, 515-525.	3.3	41
14	Viral Proteins That Bind Double-Stranded RNA: Countermeasures Against Host Antiviral Responses. Journal of Interferon and Cytokine Research, 2014, 34, 464-468.	1.2	8
15	Cellular DDX21 RNA Helicase Inhibits Influenza A Virus Replication but Is Counteracted by the Viral NS1 Protein. Cell Host and Microbe, 2014, 15, 484-493.	11.0	96
16	Dimer Interface of the Effector Domain of Non-structural Protein 1 from Influenza A Virus. Journal of Biological Chemistry, 2011, 286, 26050-26060.	3.4	58
17	Emerging antiviral targets for influenza A virus. Trends in Pharmacological Sciences, 2009, 30, 269-277.	8.7	85
18	Conserved Surface Features Form the Double-stranded RNA Binding Site of Non-structural Protein 1 (NS1) from Influenza A and B Viruses. Journal of Biological Chemistry, 2007, 282, 20584-20592.	3.4	80

#	Article	IF	Citations
19	The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: Inhibiting the 2'-5' oligo (A) synthetase/RNase L pathway. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7100-7105.	7.1	414
20	The CPSF30 Binding Site on the NS1A Protein of Influenza A Virus Is a Potential Antiviral Target. Journal of Virology, 2006, 80, 3957-3965.	3.4	157
21	VIROLOGY: Clues to the Virulence of H5N1 Viruses in Humans. Science, 2006, 311, 1562-1563.	12.6	39
22	Properties of the ISG15 E1 Enzyme UbE1L. Methods in Enzymology, 2005, 398, 32-40.	1.0	21
23	Biophysical Characterization of the Complex between Double-Stranded RNA and the N-Terminal Domain of the NS1 Protein from Influenza A Virus:â€‰ Evidence for a Novel RNA-Binding Mode. Biochemistry, 2004, 43, 1950-1962.	2.5	107
24	Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein. Virology, 2003, 309, 181-189.	2.4	233
25	The potential use of influenza virus as an agent for bioterrorism. Antiviral Research, 2003, 57, 147-150.	4.1	35
26	The 3â€²-end-processing factor CPSF is required for the splicing of single-intron pre-mRNAs in vivo. Rna, 2001, 7, 920-931.	3.5	110
27	RNA binding by the novel helical domain of the influenza virus NS1 protein requires its dimer structure and a small number of specific basic amino acids. Rna, 1999, 5, 195-205.	3.5	225
28	Influenza Virus NS1 Protein Interacts with the Cellular 30 kDa Subunit of CPSF and Inhibits 3â€² End Formation of Cellular Pre-mRNAs. Molecular Cell, 1998, 1, 991-1000.	9.7	548
29	A novel RNA-binding motif in influenza A virus non-structural protein 1. Nature Structural and Molecular Biology, 1997, 4, 891-895.	8.2	110
30	A unique cap(m7GpppXm)-dependent influenza virion endonuclease cleaves capped RNAs to generate the primers that initiate viral RNA transcription. Cell, 1981, 23, 847-858.	28.9	685